[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

[Tyr⁸]-Atrial Natriuretic Peptide (5-27), rat; [Tyr⁸]-Atriopeptin II, rat is a synthetic, tyrosine-substituted analog of rat atriopeptin II designed primarily as a precursor for radioiodination in receptor binding and autoradiography studies. This high-purity research peptide retains the core disulfide-bridged structure of the native natriuretic peptide, enabling specific interaction with natriuretic peptide receptors while providing a convenient site for radiolabeling. Supplied as a lyophilized powder with guaranteed ≥95% purity and low endotoxin levels, it serves as an essential tool for investigating ANP/NPR signaling pathways, receptor distribution, and ligand–receptor kinetics in cardiovascular and renal research models.



TECHNICAL SPECIFICATIONS


Item
Specification
Product Name
[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat
CAS NO.
/
Appearance
White to off-white lyophilized powder
Molecular Formula
C98H156N34O33S2
Molecular Weight
 2402.7g/mol 
Purity (RP-HPLC)
≥ 95.0%
Solubility

Soluble in water, phosphate-buffered saline (PBS), or dilute acetic acid (e.g., 0.1%). It is recommended to first dissolve in a small volume of 0.1% acetic acid or sterile water to prepare a 0.1–1.0 mg/mL stock solution, then dilute with assay buffer.

Endotoxin< 1.0 EU/mg
Biological Activity
This peptide is a modified analog of rat atriopeptin II / ANP(5-27), where the substitution with tyrosine at position 8 may be designed for iodination (e.g., with ¹²⁵I) to create a radioligand for receptor binding studies. It retains the ability to bind to natriuretic peptide receptors (primarily NPR-A) and stimulate cGMP production, although its affinity and potency may differ from the native peptide. Biological activity should be confirmed by receptor binding assays or cGMP accumulation assays.
Storage Conditions
Lyophilized powder: Store desiccated at –20°C or below, protected from light, for long-term stability. Reconstituted solution: Aliquot and store at ≤ –20°C; avoid repeated freeze-thaw cycles.
Stock Location
Stock in USA
MOQ
1g


1.MECHANISM OF ACTION

The peptide functions as a ligand for natriuretic peptide receptors, primarily NPR-A, by binding to the extracellular domain of these guanylyl cyclase-coupled receptors. This engagement activates intracellular guanylyl cyclase, leading to increased cyclic GMP (cGMP) production. Elevated cGMP levels activate cGMP-dependent protein kinases, resulting in vasodilation, enhanced renal sodium and water excretion, and inhibition of the renin–angiotensin–aldosterone system. The [Tyr⁸] modification does not fundamentally alter this signaling cascade but provides a site for iodination, allowing the generation of radiolabeled tracers that retain receptor binding affinity for quantitative autoradiography and competition binding assays.


2.PRODUCT INDICATIONS

This [Tyr⁸]-modified rat ANP analog is indicated exclusively for research use in preclinical studies of natriuretic peptide receptor biology and cardiovascular physiology. It is employed as a precursor for radioiodination to produce [¹²⁵I]-Tyr⁸-ANP tracers for receptor binding assays, saturation and competition studies, and autoradiographic mapping of NPR distribution in tissues. The unlabeled peptide also serves as a cold competitor in displacement experiments and can be used in functional assays to assess cGMP accumulation and vascular relaxation in cell-based and isolated tissue preparations. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.


3.CLINICAL EFFICACY OF PRODUCT

As a research reagent and radioligand precursor, [Tyr⁸]-Atrial Natriuretic Peptide (5-27), rat; [Tyr⁸]-Atriopeptin II, rat has no established clinical efficacy for therapeutic use in human patients. The product has not undergone clinical development, regulatory approval, or safety evaluation for any medical indication. While it contributes to the understanding of natriuretic peptide receptor dynamics and potential therapeutic targets for conditions like hypertension and heart failure, it remains an investigational tool for basic and translational research. Its utility is confined to laboratory applications, with no proven clinical benefits or safety profile in humans.


4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods 
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.

Premium API Oxandrolone Ucinky Manufacturing
May 25, 26
Premium API Oxandrolone Ucinky Manufacturing
Premium API Oxandrolone Ucinky Manufacturing Leading global supplier of high-purity chemical raw materials for pharmaceutical grade Oxandrolone Ucinky, combining precision engineering with industrial scale. 5000 kg Annual Output 120 Countries Served 5 Days Sample Lead Time 99.7 On-Time Delivery Industrial Precision Pure Chemical Synthesis Engineering the future of pharmaceutical intermediates with unmatched stability. Our facility stands as a global leader in the oxandrolone ucinky sector, utilizing CRYOGENIC CRYSTALLIZATION and advanced chromatography to ensure an assay purity exceeding 99.8. We integrate a fully automated closed-loop system that eliminates human error and contamination.
Clinical Benefits and Applications of Oxandrolone Therapy
May 22, 26
Clinical Benefits and Applications of Oxandrolone Therapy
Oxandrolone therapy represents a sophisticated intersection of endocrine science and regenerative medicine, primarily utilized to address muscle wasting and metabolic dysfunction. In the global pharmaceutical landscape, this specific approach to androgen therapy is valued for its unique ability to promote protein synthesis while exhibiting a lower androgenic profile compared to traditional steroids, making it a critical tool for patients recovering from severe trauma or chronic illness. From a clinical perspective, understanding the nuances of oxandrolone therapy is essential for optimizing patient outcomes in weight gain and tissue repair.
Clinical Benefits and Production of Oxandrolone Steroid
May 20, 26
Clinical Benefits and Production of Oxandrolone Steroid
The global pharmaceutical landscape has seen a significant rise in the demand for highly specialized anabolic agents, among which the oxandrolone steroid stands out due to its unique chemical profile and therapeutic versatility. As a modified version of dihydrotestosterone, this compound provides a potent means of addressing muscle wasting and metabolic deficits, making it a critical asset in both clinical rehabilitation and advanced physiological research. Understanding the nuances of this synthetic compound is essential for healthcare providers and researchers alike, as it balances efficacy with a relatively lower androgenic profile compared to other steroids.

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.